Foghorn Therapeutics is a clinical-stage biopharmaceutical company discovering and developing medicines targeting genetically determined dependencies within the chromatin regulatory system. Co.'s product candidates are: FHD-286, which is a selective, allosteric and small-molecule, enzymatic inhibitor of BRG1 and BRM, that it is developing for the potential treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, which is a selective and intravenous, small molecule protein degrader of BRD9, a component of a form of the BAF complex that Co. is developing in clinical study in synovial sarcoma. The FHTX YTD return is shown above.
The YTD Return on the FHTX YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether FHTX YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the FHTX YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|